The MegaR systematizes the challenges of ligand-free GPCR/GPCR-antagonist structure elucidation.

GPCR average molecular weight can vary considerably due to structural and size differences. The introduction of M protein enables engineered GPCRs to achieve enhanced stability, with molecular weights exceeding 100 kDa. This characteristic renders the protein suitable for low-temperature electron microscopy structural determination as well as for structure-based drug design (SBDD) and artificial intelligence-driven drug design (AIDD)